News and Trends 4 Oct 2017
Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy
Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both companies signed a billion-dollar partnership. Immatics, a company based in Tübingen specialized in cancer immunotherapy, has announced that its Series E round has reached $58M (€50M). Existing investors including dievini Hopp Biotech, Wellington Partners, and AT Impf took part in the fundraising, which […]